

## **MEDICARE FORM**

## Trelstar® (triptorelin pamoate) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

For Ohio MMP: FAX: 1-855-734-9389 PHONE: 1-855-364-0974 For other lines of business: Please use other form

Note: Trelstar is non-preferred. The preferred product is Eligard.

Firmagon is also a preferred product.

Please indicate: Start of tr			last treatment/	/	/					
Precertification Requested By						:		Fax	::	
A. PATIENT INFORMATION										
First Name:			Last Name:					DOB:		
Address:				City:				State:	Z	IP:
Home Phone:	Work Ph	one:		Cell [	Phone:			Email:		
Patient Current Weight: lbs	s orkgs	Patien	t Height: inches	or _	cms	Allergies:		<u>I</u>		
B. INSURANCE INFORMATION			<u> </u>							
Aetna Member ID #:			Does patient have other coverage? ☐ Yes ☐ No							
Group #:			If yes, provide ID#: Carrier Name:							
Insured:			Insured:							
Medicare: ☐ Yes ☐ No If yes	-		Me	edicai	d: ∐ Yes	☐ No If ye	s, prov	ide ID #:		
C. PRESCRIBER INFORMATIO	N					(Oh.	- 1 - 0 -	· □ M D		
First Name:			Last Name:	<del>Та.,</del>		(Che	eck ∪ne	i		O.
Address:			Т	City				State:		IP:
Phone: Fa	<b>x</b> :		St Lic #:	NPI	#:	DE	:A #:	т	U	IPIN:
Provider Email:			Office Contact Name:	:				Phone:		
Specialty (Check one):   Once	ologist 🗌 Endo	ocrinol	ogist							
D. DISPENSING PROVIDER/AD	MINISTRATION	INFOR	RMATION							
Place of Administration:					-	Provider/Ph		y: Patient	Selecte	ed choice
	Physician's Office					n's Office		☐ Retail Pl	harmac	у
Outpatient Infusion Center				-  [	☐ Specialty Pharmacy ☐ Other					
Center Name: Home Infusion Center	Phone:			- N	Name:					
Agency Name:				-	Address:					_
☐ Administration code(s) (CPT):				C	City:			State:	;	ZIP:
Address:			<u> </u>							
City:Phone:				•						
TIN:				-   1	NPI:					
NPI:				_						
E. PRODUCT INFORMATION										
Request is for: Trelstar (triptor	elin pamoate) Do	ose:			Frequer	ncy:				
F. DIAGNOSIS INFORMATION						=				
Primary ICD Code:			Secondary ICD Code				Other I	CD Code: _		
G. CLINICAL INFORMATION -	Required clinical i	informa	•		s entirety for	r all precertif	fication	requests.		
For Initiation Requests (clinical c										
☐ Gender dysphoria										
Yes No Is the requested medication being prescribed for pubertal suppression in an adolescent patient?										
<ul> <li>Yes ☐ No Is the patient undergoing gender reassignment?</li> <li>☐ Yes ☐ No Will the patient receive the requested medication concomitantly with gender affirming hormones?</li> </ul>										
Please indica	ate the Tanner Stag		berty the patient has read							age V 🔲 Unknown
☐ Preservation of ovarian funct										
☐ Yes ☐ No Is the patient premenopausal and undergoing chemotherapy?										
☐ Prostate cancer  Note: Trelstar is non-preferred. The preferred product is Eligard. Firmagon is also a preferred product.										
☐ Yes ☐ No Has the patient had a trial and failure, intolerance, or contraindication to Eligard?										
Please explain if there are any other	er medical reason(s	s) that t	he patient cannot use E	Eligard	when indicate	ted for the pa	itient's c	liagnosis?		



## **MEDICARE FORM**

## Trelstar<sup>®</sup> (triptorelin pamoate) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

For Ohio MMP:

**FAX:** 1-855-734-9389 **PHONE:** 1-855-364-0974

For other lines of business: Please use other form

Note: Trelstar is non-preferred. The preferred product is Eligard. Firmagon is also a preferred product.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB				
G. CLINICAL INFORMATION (contin	<b>ued)</b> – Required clinical information mus	st be completed in its <u>entirety</u> for all prece	rtification requests.				
For Continuation Requests (clinical of	documentation required for all request	<u>ts):</u>					
☐ Gender dysphoria							
	nedication being prescribed for pubertal s						
└────────────────────────────────────	s the patient undergoing gender transitio	n?					
☐ Yes ☐ No Will the patient receive the requested medication concomitantly with gender affirming hormones?							
Please indicate th	e Tanner Stage of puberty the patient has	s reached: 🗌 Stage I 🗌 Stage II 🗎 Stage	III ☐ Stage IV ☐ Stage V ☐ Unknown				
☐ Preservation of ovarian function							
☐ Yes ☐ No Is the patient prem	nenopausal and still undergoing chemoth	erapy?					
☐ Prostate cancer							
☐ Yes ☐ No Has the patient ha	d prior therapy with Trelstar within the la	st 365 days?					
Yes No Has the patient experienced clinical benefit to therapy while receiving the requested drug (e.g., serum testosterone less than 50 ng/dl)?							
☐ Yes ☐ No Has the patient experie	enced an unacceptable toxicity while rec	eiving the requested drug?					
H. ACKNOWLEDGEMENT							
Request Completed By (Signature	Required):		Date: /				
any insurance company by providing		a medical procedure or service with the als material information for the purpose will penalties					

The plan may request additional information or clarification, if needed, to evaluate request.